In our study, the proportions of patients with a good prognosis for anti-NMDAR, anti-LGI1, anti-GABABR, and anti-CASPR2 encephalitis were 87.5%, 92.0%, 42.1%, and 71.4%, respectively. This evidence concerns the gene CNTNAP2 and viral encephalitis.